PLIN-2 is upregulated in NAFLD animals and patients and promotes the accumulation of triglycerides, inhibits the oxidation of FFAs, and alters glucose tolerance [35]. This evidence concerns the gene PLIN2 and metabolic dysfunction-associated steatotic liver disease.